225 related articles for article (PubMed ID: 30010219)
1. Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β-thalassemia.
Shariati L; Rohani F; Heidari Hafshejani N; Kouhpayeh S; Boshtam M; Mirian M; Rahimmanesh I; Hejazi Z; Modarres M; Pieper IL; Khanahmad H
J Cell Biochem; 2018 Nov; 119(11):9357-9363. PubMed ID: 30010219
[TBL] [Abstract][Full Text] [Related]
2. Inducing indel mutation in the SOX6 gene by zinc finger nuclease for gamma reactivation: An approach towards gene therapy of beta thalassemia.
Modares Sadeghi M; Shariati L; Hejazi Z; Shahbazi M; Tabatabaiefar MA; Khanahmad H
J Cell Biochem; 2018 Mar; 119(3):2512-2519. PubMed ID: 28941328
[TBL] [Abstract][Full Text] [Related]
3. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
5. Genetic disruption of the KLF1 gene to overexpress the γ-globin gene using the CRISPR/Cas9 system.
Shariati L; Khanahmad H; Salehi M; Hejazi Z; Rahimmanesh I; Tabatabaiefar MA; Modarressi MH
J Gene Med; 2016 Oct; 18(10):294-301. PubMed ID: 27668420
[TBL] [Abstract][Full Text] [Related]
6. SOX6 Downregulation Induces
Li J; Lai Y; Luo J; Luo L; Liu R; Liu Z; Zhao W
Biomed Res Int; 2017; 2017():9496058. PubMed ID: 29333458
[TBL] [Abstract][Full Text] [Related]
7. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
[TBL] [Abstract][Full Text] [Related]
10. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
11. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
[TBL] [Abstract][Full Text] [Related]
12. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
13. Acyclovir induces fetal hemoglobin via downregulation of γ-globin repressors, BCL11A and SOX6 trans-acting factors.
Ali H; Khan F; Ghulam Musharraf S
Biochem Pharmacol; 2021 Aug; 190():114612. PubMed ID: 34010599
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA HBBP1 enhances γ-globin expression through the ETS transcription factor ELK1.
Ma SP; Xi HR; Gao XX; Yang JM; Kurita R; Nakamura Y; Song XM; Chen HY; Lu DR
Biochem Biophys Res Commun; 2021 May; 552():157-163. PubMed ID: 33744764
[TBL] [Abstract][Full Text] [Related]
16. Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.
Ajami M; Atashi A; Kaviani S; Kiani J; Soleimani M
J Cell Biochem; 2020 Feb; 121(2):1420-1430. PubMed ID: 31596028
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.
Khiabani A; Kohansal MH; Keshavarzi A; Shahraki H; Kooshesh M; Karimzade M; Gholizadeh Navashenaq J
Mol Genet Genomics; 2023 Jan; 298(1):1-11. PubMed ID: 36403178
[TBL] [Abstract][Full Text] [Related]
18. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
19. Trienone analogs of curcuminoids induce fetal hemoglobin synthesis via demethylation at
Nuamsee K; Chuprajob T; Pabuprapap W; Jintaridth P; Munkongdee T; Phannasil P; Vadolas J; Chaichompoo P; Suksamrarn A; Svasti S
Sci Rep; 2021 Apr; 11(1):8552. PubMed ID: 33879818
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.
Xu J; Sankaran VG; Ni M; Menne TF; Puram RV; Kim W; Orkin SH
Genes Dev; 2010 Apr; 24(8):783-98. PubMed ID: 20395365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
